Compass Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Compass Therapeutics, Inc. (CMPX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CMPX insiders buying or selling?
In the last 12 months, Compass Therapeutics, Inc. insiders reported 2 open-market purchases ($21.3K) and 0 sales ($0) — net buying of $21.3K. Since June 2020, Trabud has recorded 43 Form 4 filings for CMPX: 39 buys ($60.6M) and 4 sells ($11.6M).
Source: SEC EDGAR Form 4
Key Statistics (June 2020 – Oct 2, 2026)
Total Form 4 filings
43
SEC EDGAR
Insider filers
8
Insider buys (39)
$60.6M
Insider sells (4)
$11.6M
Insider sentiment
Net buyingNet insider flow of $49.1M in net buying since June 2020, and $21.3K in net buying over the last 12 months. 2 insider buys in the last 90 days.
Recent CMPX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Neil Lerner | Chief Accounting Officer | Purchase | 20.0K | $0.92 | $18.4K | SEC ↗ |
| Sep 25, 2026 | Neil Lerner | Chief Accounting Officer | Purchase | 2.5K | $1.14 | $2.9K | SEC ↗ |
| May 27, 2025 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 10.0K | $2.11 | $21.1K | SEC ↗ |
| Apr 11, 2025 | Carl L Gordon | Director, 10% Owner | Sale | 3.6M | $1.59 | $5.7M | SEC ↗ |
| Apr 11, 2025 | ORBIMED ADVISORS LLC | Director, 10% Owner | Sale | 3.6M | $1.59 | $5.7M | SEC ↗ |
| Apr 8, 2025 | Jonathan Anderman | Gen Counsel & Corporate Sec | Purchase | 20.0K | $1.54 | $30.8K | SEC ↗ |
| Apr 8, 2025 | Neil Lerner | CHIEF ACCOUNTING OFFICER | Purchase | 20.0K | $1.42 | $28.4K | SEC ↗ |
| Mar 10, 2023 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 10.0K | $3.37 | $33.7K | SEC ↗ |
| Feb 27, 2023 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 20.0K | $3.98 | $79.6K | SEC ↗ |
| Feb 15, 2023 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 20.0K | $3.86 | $77.2K | SEC ↗ |
| Jan 31, 2023 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 20.0K | $4.05 | $81.0K | SEC ↗ |
| Jan 24, 2023 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 20.0K | $4.19 | $83.8K | SEC ↗ |
| Nov 25, 2022 | Vered Bisker-Leib | Chief Operating Officer | Sale | 24.5K | $4.23 | $103.7K | SEC ↗ |
| Nov 22, 2022 | Vered Bisker-Leib | Chief Operating Officer | Sale | 22.3K | $4.36 | $97.0K | SEC ↗ |
| Nov 10, 2022 | ORBIMED ADVISORS LLC | Director, 10% Owner | Purchase | 402.0K | $3.21 | $1.3M | SEC ↗ |
| Nov 10, 2022 | Carl L Gordon | Director, 10% Owner | Purchase | 402.0K | $3.21 | $1.3M | SEC ↗ |
| Sep 28, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 10.0K | $2.32 | $23.2K | SEC ↗ |
| Sep 27, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 15.0K | $2.27 | $34.0K | SEC ↗ |
| Sep 8, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 15.0K | $3.03 | $45.5K | SEC ↗ |
| Sep 1, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 15.0K | $2.83 | $42.5K | SEC ↗ |
| Aug 17, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 15.0K | $3.05 | $45.8K | SEC ↗ |
| Aug 10, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 15.0K | $2.64 | $39.6K | SEC ↗ |
| Aug 2, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 15.0K | $2.58 | $38.7K | SEC ↗ |
| Jun 21, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 20.0K | $2.80 | $56.0K | SEC ↗ |
| Jun 17, 2022 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 20.0K | $2.34 | $46.8K | SEC ↗ |
Showing the 25 most recent of 43 Form 4 filings for Compass Therapeutics, Inc..
Most active CMPX insiders
- Schuetz Thomas J.23 filings
- Carl L Gordon6 filings
- ORBIMED ADVISORS LLC6 filings
- Neil Lerner3 filings
- Vered Bisker-Leib2 filings
Ask anything about CMPX insider activity
Use Trabud's AI agent to query Compass Therapeutics, Inc.'s Form 4 history in plain English — "Show me CMPX CEO purchases this year" or compare it against any other ticker.
Open the AI agentCMPX insider trading FAQ
Are Compass Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Compass Therapeutics, Inc. insiders reported 2 open-market purchases ($21.3K) and 0 sales ($0) — net buying of $21.3K. Since June 2020, Trabud has recorded 43 Form 4 filings for CMPX: 39 buys ($60.6M) and 4 sells ($11.6M). Over the full record that is net buying of $49.1M.
How many insiders trade CMPX stock?
8 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Compass Therapeutics, Inc.. The most recent filing was accepted on Oct 2, 2026.
Where does Trabud get CMPX insider trading data?
All CMPX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.